Gene therapy trial aims to halt vision loss in rare eye disease
NCT ID NCT06699108
Summary
This study is testing whether a one-time gene therapy injection called VGR-R01 can slow or stop vision loss in adults with Bietti Crystalline Dystrophy, a rare inherited retinal disease. It will enroll 45 participants, with two-thirds receiving the therapy in one eye and the rest serving as a control group for comparison. The main goal is to see if the treatment improves or stabilizes visual acuity compared to no treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INHERITED RETINAL DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Vitalgen Biopharma Co.,Ltd.
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.